代谢相关脂肪性肝病患者发生肌少症性肥胖的风险因素和预测模型构建*

周瑜, 钱丽雅, 徐洁, 马晓旭

中西医结合肝病杂志 ›› 2024, Vol. 34 ›› Issue (8) : 691-694.

PDF(3137 KB)
PDF(3137 KB)
中西医结合肝病杂志 ›› 2024, Vol. 34 ›› Issue (8) : 691-694. DOI: 10.3969/j.issn.1005-0264.2024.008.005
临床研究

代谢相关脂肪性肝病患者发生肌少症性肥胖的风险因素和预测模型构建*

  • 周瑜, 钱丽雅, 徐洁, 马晓旭
作者信息 +

Construction of a risk prediction model for sarcopenic obesity in patients with metabolism related fatty liver disease

  • ZHOU Yu, QIAN Li-ya, XU Jie, MA Xiao-xu
Author information +
文章历史 +

摘要

目的:探讨代谢相关脂肪性肝病(MAFLD)患者肌少症性肥胖(SO)发生的危险因素,构建预测模型。方法:回顾性选择2018年6月至2023年6月我院收治的410例MAFLD患者,根据SO检出情况将MAFLD患者分为SO组(32例)和非SO组(378例)。多因素Logistic回归分析MAFLD患者发生SO的危险因素并构建预测模型,通过Hosmer-Lemeshow检验和受试者工作特征(ROC)曲线验证预测模型性能。结果:SO组年龄大于非SO组(P<0.05),男性、糖尿病、Child-Pugh分级C级、每周运动频率3次以下比例高于非SO组(P<0.05),BMI、HbA1C、HOMA-IR、hs-CRP高于非SO组(P<0.05),白蛋白低于非SO组(P<0.05)。年龄偏大、高hs-CRP、高HOMA-IR、Child-Pugh分级C级是MAFLD患者发生SO的危险因素(P<0.05)。预测模型预测MAFLD患者发生SO的曲线下面积为0.829(95%CI=0.783~0.872),Hosmer-Lemeshow检验P>0.05。结论:老龄、炎症、胰岛素抵抗、肝功能是MAFLD患者发生SO的相关因素,基于上述风险因素构建的预测模型具有较高的预测 MAFLD患者发生SO的效能。

Abstract

Objective: To explore the risk factors for the development of sarcopenic obesity (SO) in patients with Metabolic Associated Fatty Liver Disease (MAFLD) and to construct a predictive model. Methods: The clinical data of 410 patients with MAFLD admitted to our hospital from June 2018 to June 2023 were retrospectively selected, and the patients with MAFLD were divided into SO group (32 cases) and non-SO group (378 cases) according to the detection of SO. Multivariate Logistic regression was used to analyze the risk factors for developing SO in MAFLD patients and to construct a prediction model. The performance of the prediction model was verified by Hosmer-Lemeshow test and receiver operating characteristic (ROC) curve. Results: SO group was older than non-SO group (P<0.05), male, diabetes, Child-Pugh grade C, exercise frequency less than 3 times/week ratio were higher than non-SO group (P<0.05), BMI, HbA1C, HOMA-IR, hs-CRP were higher than non-SO group (P<0.05). Albumin was lower than that in non-SO group (P<0.05). Higher age, hs-CRP, HOMA-IR and Child-Pugh grade C were the risk factors for MAFLD patients to complicated with SO (P<0.05). The area under the curve of SO in patients with pre-MAFLD predicted by the model was 0.829(95%CI=0.783~0.872). Conclusion: Age, chronic inflammation, insulin resistance and elevated liver function are risk factors for SO in patients with MAFLD. The prediction model based on the above risk factors has high efficacy in predicting SO in patients with MAFLD.

关键词

代谢相关脂肪性肝病 / 肌少症性肥胖 / 风险因素 / 预测模型

Key words

Metabolic associated fatty liver disease / sarcopenic obesity / risk factors / prediction model

引用本文

导出引用
周瑜, 钱丽雅, 徐洁, 马晓旭. 代谢相关脂肪性肝病患者发生肌少症性肥胖的风险因素和预测模型构建*[J]. 中西医结合肝病杂志, 2024, 34(8): 691-694 https://doi.org/10.3969/j.issn.1005-0264.2024.008.005
ZHOU Yu, QIAN Li-ya, XU Jie, MA Xiao-xu. Construction of a risk prediction model for sarcopenic obesity in patients with metabolism related fatty liver disease[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2024, 34(8): 691-694 https://doi.org/10.3969/j.issn.1005-0264.2024.008.005
中图分类号: R575.5   

参考文献

[1] Pipitone RM,Ciccioli C, Infantino G,et al.MAFLD:a multisystem disease[J].Ther Adv Endocrinol Metab,2023,14:20420188221145549.
[2] 施漪雯,肖倩倩,范建高.亚太肝脏研究协会代谢相关脂肪性肝病临床诊疗指南简介[J]. 中华肝脏病杂志,2020,28(11):915-917.
[3] Zhao Q,Yin Y,Deng Y.Metabolic associated fatty liver disease and sarcopenia additively increase mortality:a real-world study[J]. Nutr Diabetes, 2023, 13(1):21.
[4] Nishikawa H, Enomoto H, Nishiguchi S,et al. Sarcopenic obesity in liver cirrhosis: possible mechanism and clinical impact[J]. Int J Mol Sci, 2021, 22(4):1917.
[5] Eslam M, Sarin SK, Wong VW,et al. The asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020,14(6):889-919.
[6] Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3):300-307.
[7] 李红娟,杨柳,张楠.身体质量指数作为肥胖筛查标准的判别准确性评价[J].中国预防医学杂志,2014,15(6):571-575.
[8] Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease: an interna-tional expert consensus statement[J]. J Hepatol, 2020, 73(1):202-209.
[9] Yi Y, Wang C, Ding Y,et al. Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: analysis of the national health and nutrition examination survey III[J]. Front Endocrinol (Lausanne), 2023, 14:1101892.
[10] Liu C, Wong PY, Chung YL,et al. Deciphering the "obesity paradox" in the elderly: a systematic review and meta-analysis of sarcopenic obesity[J]. Obes Rev, 2023, 24(2):e13534.
[11] Chun HS, Lee M, Lee HA,et al. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21(9):2298-2307.e18.
[12] Polyzos SA, Margioris AN. Sarcopenic obesity[J]. Hormones (Athens), 2018, 17(3):321-331.
[13] de Sire A,Ferrillo M,Lippi L,et al.Sarcopenic dysphagia,malnutrition,and oral frailty in elderly:a comprehensive review[J]. Nutrients, 2022 ,14(5):982.
[14] Oh C, Jeon BH, Reid Storm SN,et al. The most effective factors to offset sarcopenia and obesity in the older Korean: physical activity, vitamin d, and protein intake[J]. Nutrition, 2017, 33:169-173.
[15] Wei P, Sun FD, Zuo LM,et al. Critical residues and motifs for homodimerization of the first transmembrane domain of the plasma membrane glycoprotein CD36[J]. J Biol Chem, 2017, 292(21):8683-8693.
[16] Lim JP, Leung BP, Ding YY,et al. Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesi-ty[J]. Clin Interv Aging, 2015, 10:605-609.
[17] Yang CW,Li CI,Li TC,et al.Association of sarcopenic obesity with higher serum high-sensitivity c-reactive protein levels in chinese older males-a community-based study(taichung community health study-elderly,TCHS-E)[J].PLoS One,2015,10(7):e0132908.
[18] Park CH, Do JG, Lee YT,et al. Sarcopenic obesity associated with high-sensitivity C-reactive protein in age and sex comparison: a two-center study in South Korea[J].BMJ Open,2018,8(9):e021232.
[19] Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequenc-es[J]. Int J Mol Sci, 2020, 21(2):494.
[20] Wang M, Tan Y, Shi Y,et al. Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments[J]. Front Endocrinol (Lausanne), 2020 ,11:568.
[21] Hanai T, Shiraki M, Ohnishi S,et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis[J]. Hepatol Res, 2016, 46(8):743-751.
[22] Johnston HE, Takefala TG, Kelly JT,et al. The effect of diet and exercise interventions on body composition in liver cirrhosis: a systematic review[J]. Nutrients, 2022 , 14(16):3365.
[23] Salles J, Chanet A, Guillet C,et al. Vitamin D status modulates mitochondrial oxidative capacities in skeletal muscle: role in sarcopenia[J]. Commun Biol, 2022, 5(1):1288.

基金

* 江苏医药职业学院校地协同创新研究项目(No.20239610)
PDF(3137 KB)

376

Accesses

0

Citation

Detail

段落导航
相关文章

/